Total Funding
95
77
Total FundingSeries C raised
Growth Score
15 pts
Heat Score
61 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
919
Boundless Bio is a precision oncology company that develops therapeutics directed against extrachromosomal DNA in aggressive cancers.
- Zachary Hornby: Chief Executive Officer & PresidentPast Role: Ignyta, CFO and VP, Corporate Development
- Benjamin Cravatt: Director and Co-FounderPast Role: ActivX Biosciences, Co-Founder
About the Company
Boundless Bio is a company that develops novel cancer therapeutics intended to understand and treat untraceable cancers. It aims to be the biopharma company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable cancers.
